Cost Effectiveness of ACE Inhibitor Treatment for Patients with Type 1 Diabetes Mellitus

被引：0

作者：

Frederick B. Dong

Stephen W. Sorensen

Diane L. Manninen

Theodore J. Thompson

Venkat Narayan

Carlyn E. Orians

Edward W. Gregg

Richard C. Eastman

Erik J. Dasbach

William H. Herman

Jeffrey M. Newman

Andrew S. Narva

David J. Ballard

Michael M. Engelgau

机构：

[1] Battelle,Division of Diabetes Translation

[2] Centers for Public Health Research and Evaluation,undefined

[3] Centers for Disease Control and Prevention,undefined

[4] Cygnus,undefined

[5] Inc.,undefined

[6] Merck & Co.,undefined

[7] University of Michigan,undefined

[8] Internal Medicine and Epidemiology,undefined

[9] Sutter Health Institute for Research and Education,undefined

[10] Indian Health Kidney Disease Program,undefined

[11] Health Care Research and Improvement,undefined

[12] Baylor Health Care System,undefined

[13] Centers for Disease Control and Prevention,undefined

来源：

PharmacoEconomics | 2004年 / 22卷

关键词：

Captopril; Glycaemic Control; Relative Risk Reduction; Albumin Excretion Rate; Relative Risk Adjustment;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Objective: Current guidelines recommend treating patients with type 1 diabetes mellitus with ACE inhibitors after the onset of microalbuminuria. Recent clinical trials have shown ACE inhibitors can affect the development of nephropathy when initiated prior to the onset of microalbuminuria. Our objective is to examine the cost effectiveness of treating adults aged over 20 years with an ACE inhibitor (captopril) immediately following diagnosis of type 1 diabetes versus treating them after the onset of microalbuminuria.

引用

页码：1015 / 1027

页数：12

共 50 条

[1] Cost effectiveness of ACE inhibitor treatment for patients with type 1 diabetes mellitus
Dong, FB
Sorensen, SW
Manninen, DL
Thompson, TJ
Narayan, V
Orians, CE
Gregg, EW
Eastman, RC
Dasbach, EJ
Herman, WH
Newman, JM
Narva, AS
Ballard, DJ
Engelgau, MM
PHARMACOECONOMICS, 2004, 22 (15) : 1015 - 1027
[2] COST-EFFECTIVENESS OF INSULIN DEGLUDEC TREATMENT IN PATIENTS WITH TYPE1 AND TYPE 2 DIABETES MELLITUS: A SYSTEMATIC REVIEW
Yue, X.
Guan, H. J.
Wu, J.
Bai, X.
VALUE IN HEALTH, 2016, 19 (07) : A898 - A898
[3] Safety, Effectiveness, and Cost Effectiveness of Metabolic Surgery in the Treatment of Type 2 Diabetes Mellitus
Villamizar, Nestor
Pryor, Aurora D.
JOURNAL OF OBESITY, 2011, 2011
[4] ACE Inhibitor and Angiotensin II Type 1 Receptor Antagonist Therapies in Elderly Patients with Diabetes Mellitus Are They Underutilized?
Pappoe, Lamioko Shika
Winkelmayer, Wolfgang C.
DRUGS & AGING, 2010, 27 (02) : 87 - 94
[5] COST-EFFECTIVENESS OF DAPAGLIFLOZIN IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS IN PERU
Elgart, J. F.
Gonzalez, L.
Prestes, M.
Manrique, H.
Solorzano, J.
Gagliardino, J. J.
VALUE IN HEALTH, 2016, 19 (03) : A203 - A203
[6] Cost of diabetes mellitus type 1 treatment: difficulties of the families
Vintimilla Castro, Amparito del Rocio
Alves Grossi, Sonia Aurora
ACTA PAULISTA DE ENFERMAGEM, 2008, 21 (04) : 624 - 628
[7] Cost-Effectiveness of Liraglutide Versus Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus in the UK
Vega-Hernandez, Gabriela
Wojcik, Radek
Schlueter, Max
DIABETES THERAPY, 2017, 8 (03) : 513 - 530
[8] Cost-Effectiveness of Liraglutide Versus Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus in the UK
Gabriela Vega-Hernandez
Radek Wojcik
Max Schlueter
Diabetes Therapy, 2017, 8 : 513 - 530
[9] Cost-effectiveness of dapagliflozin as an adjunct to insulin for the treatment of type 1 diabetes mellitus in the United Kingdom
Bennett, Hayley
Tank, Amarjeet
Evans, Marc
Bergenheim, Klas
McEwan, Phil
DIABETES OBESITY & METABOLISM, 2020, 22 (07): : 1047 - 1055
[10] COST-EFFECTIVENESS OF EMPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN ARGENTINA
Rodriguez, L.
Lew, D.
VALUE IN HEALTH, 2020, 23 : S115 - S115

← 1 2 3 4 5 →